Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation

Abstract

Data related to the disease course of patients with systemic lupus erythematosus (SLE) with special attention tothepersistence of disease activity in the long term are scarce. At this moment reliable figures are only knownabout the survival rate as a measure of outcome. The aim of this multicenter study was to describe the outcome ofSLE patients with a disease duration of greater than 10 y.Outcome parameters were two disease activity-scoring systems (SLEDAI and ECLAM), the end organ damage (SLICC/ACR damage index) and treatment. Our results are derived from 187SLE patients followed at 10 different centres in Europe over a period of 1 y. Serious clinical signs or exacerbations, defined by the occurrence or detoriation of already existing symptoms of renal and cerebral nervous systems were observed in 2 ‐ 11% of the patients,seizures and psychosis in 3%, proteinuria in 11% and an increase in serum creatinine in 5% of the patients. No change took place in the overall damage index. Yet, the diseasecourse in most patients was characterized by periods of tiredness (42 ‐ 60%), arthritis (20 ‐ 25%), skin involvement such as malar rash (32 ‐ 40%), migraine (15 ‐ 20%), anaemia(15%) and leucopenia (17 ‐ 19%). Summarizing these results it is shown that patients, still under care after such a long time of having this disease, do have a disease that is far from extinguished.

Keywords

SLE disease activity SLEDAI ECLAM damage index

Get full access to this article

View all access options for this article.

References

Massardo L , Martinez ME , Jacobelli S , Villarrod L , Rozenberg H , Rivero S. Survival of Chilean patients with systemic lupus erythematosus . Semin Arthritis Rheum 1994; 24: 1 ‐ 11 .

Abu-Shakra , Urowitz MB , Gladman DD , Gough J. Mortality studies in systemic lupus erythematosus. Results from a single centre: II predicted variables for mortality . J Rheumatol 1995; 22: 1265 ‐ 1270 .

Swaak AJG , Nossent J , Bronsveld W et al. Systemic lupus erythematosus: I outcome and survival. Dutch experience with 110 patients studied prospectively . Ann Rheum Dis 1989;48: 447 ‐ 454 .

Gladman DD . Prognosis and treatment of systemic lupus erythematosus . Curr Opin Rheumatol 1996; 8: 430 ‐ 437 .

Ward MM , Pyun E. Studenski S. Longterm survival in systemic lupus erythematosus: patient characteristics associated with poorer outcome . Arthritis Rheum 1995; 38: 274 ‐ 283 .

Nossent J. Course and prognosis of systemic lupus erythematosus disease activity index in Black Caribbean patients . Semin Arthritis Rheum 1993; 23: 16 ‐ 21 .

Kumar A , Malaviya AH , Singh YN , Adya CM , Kakar R. Survival in patients with systemic lupus erythematosus in India .Rheumatol Int 1992; 12: 107 ‐ 109 .

Albert DA , Hadler NM , Ropes MW . Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus . Arthritis Rheum 1979; 22: 945 ‐ 953 .

Dubois EL . Systemic lupus erythematosus: recent advancesin its diagnosis and treatment . Ann Intern Med 1956; 45: 163 ‐ 184 .

10.

Ropes MW . Observations on the natural course of disseminated lupus erythematosus . Medicine (Baltimore) 1964; 43: 387 ‐ 391 .

11.

Ben-Asher S. Recurrent acute lupus erythematosus disseminatus: report of case which survived 23 years after onsetof systemic lupus erythematosus . Ann Intern Med 1951; 34: 243 ‐ 248 .

12.

Drenkard C , Villa AR , Garcia-Padilla C , Pérez-Vásquez ME , Alarcón-Segovia D. Remission of systemic lupus erythematosus . Medicine 1996; 75: 88 ‐ 98 .

13.

Bombardier C , Gladman DD , Urowitz MB , Charron D , Chang CH . The development and validation of the SLE disease activity index (SLEDAI). Arthritis Rheum 1992; 35: 630 ‐ 640 .

14.

Vitali C , Bencivelli W , Isenberg DA et al. Disease activity in systemic lupus erythematosus report of the consensus group of the European workshop of Rheumatology researchII identification of the variables indicative of disease activity and their use in the development of our activity score . Clin Exp Rheumatol 1992; 10: 541 ‐ 547 .

15.

Gladman DD , Ginzler E , Goldsmith C , Fortin P , Liang M , Urowitz M. The development and initial validation of the systemic international collaboratory clinical/American college of rheumatology damage index for systemic lupus erythematosus . Arthritis Rheum 1996; 39: 363 ‐ 369 .

16.

Swaak AJG , van den Brink HG , Smeenk RJT et al. Systemiclupus erythematosus: disease outcome in patients with a disease duration of at least 10 years. First evaluation . Rheumatology 1999; 38: 953 ‐ 958 .

17.

Tan EM , Cohen AS , Fries JF . The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271 ‐ 77 .

18.

American Rheumatism association Glossary Committee . Dictionary of the Rheumatic Diseases. Signs and Symptoms Vol 1, 1st edn. Contact Associates International: Bayport, NY ;1982, pp 1 ‐ 80.

19.

Scleznick MJ , Fries JJ . Variables associated with decreased survival in systemic lupus erythematosus . Semin Arthritis Rheum 1991; 21: 73 ‐ 80 .

20.

Tucker LB , Meno S , Schalla JG , Isenberg DA . Adult and childhood-onset systemic lupus erythematosus: a comparisonof onset, clinical features, serology and outcome . Br J Rheumatol 1995; 34: 866 ‐ 872 .

21.

Lehman TJA , McCurdy DK , Bernstein BH , King KK , Hanson V. Systemic lupus erythematosus the first decade oflife . Pediatrics 1989; 83: 235 ‐ 239 .

22.

Wallace DJ , Podell T , Weiner J , Klinenberg JR , Forouzesh S , Dubois EL . Systemic lupus erythematosus survival patterns: experience with 609 patients JAMA 1981; 245: 934 ‐ 938 .

23.

Reveille JD , Bartolucci A , Alarcón GS . Prognosis in systemic lupus erythematosus: negative impact ofincreasing at onset; black race, and thrombopenia, as wellas causes of death . Arthritis Rheum 1990; 37: 48-48 .

24.

Ginzler EM , Schorn K. Outcome and prognosis in systemiclupus erythematosus . Rheum Dis Clin N Am 1998; 14: 67 ‐ 78 .

25.

Klippel JH . Systemic lupus erythematosus: demographics,prognosis and outcome . J Rheumatol 1977; 24(Suppl 48): 67 ‐ 71 .

26.

Dubois EL . Systemic lupus erythematosus: recent advances in its diagnosis and treatment . Ann Intern Med 1956; 45: 163 ‐ 184 .

27.

Gladman DD , Goldsmith CH , Urowitz MB et al. Cross-cultural validation of three disease activity indices in systemic lupus erythematosus (SLE). J Rheumatol 1992; 19: 608 ‐ 611 .

28.

Petri M , Hellmann D , Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting . J Rheumatol 1992; 19: 53 ‐ 59 .

29.

Hawkes G , Gabriel S , Bombardier C , Goldsmith C , Caron D , Gladman DD . A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus (SLE). J Rheumatol 1993; 20: 657 ‐ 660 .

30.

Gladman DD , Goldsmith CH , Urowitz MB et al. Sensitivityto change of 3 systemic lupus erythematosus disease activity indices: international validation . J Rheumatol 1994; 21: 1468 ‐ 1471 .

31.

Gladman DD , Urowitz MB , Goldsmith CH et al. The reliability of the systemic international collaborating clinics/American college of rheumatology damage index in patients with systemic lupus erythematosus . Arthritis Rheum 1997; 40: 809 ‐ 813 .

32.

Stoll T , Stucki G , Gordon C , Isenberg DA . A damage index for lupus patients: where are we now . Lupus 1997; 6: 619‐ 622 .

33.

Rahman P , Aquero S , Hallett D , Gladman D , Urowitz MB . Hypertension and vascular events in systemic lupus erythematosus . Arthritis Rheum 1999; 42(Suppl 9): S215-S215 .

34.

Stahl-Hallengren C , Jonson A , Nived O , Sturvelt G. Incidence studies of systemic lupus erythematosus in southern Sweden: increasing age decreasing frequency of renal manifestations and good prognosis . J Rhematol 2000; 27: 685 ‐ 691 .